PTBI News Alert Plasmatech Biopharmaceuticals Inc. (PTBI) 3.10
Post# of 64074
Posted On: 02/15/2015 10:27:33 AM
Plasmatech Biopharmaceuticals Inc. (PTBI) 3.10 $PTBI
PlasmaTech Biopharmaceuticals To Present at 17th Annual BIO CEO & Investor Conference
PR Newswire - Fri Feb 06, 10:13AM CST
PlasmaTech Biopharmaceuticals, Inc. (NASDAQ: PTBI), a biopharmaceutical company advancing protein biologic therapies and oncology supportive care products, announced today that Scott Schorer, CEO, will be presenting a corporate update at the 17th Annual BIO CEO & Investor Conference. The presentation will take place on Monday, February 9, 2015, at 5:00 pm ET in the Park South room at the Waldorf Astoria Hotel in New York, NY. Management from PTBI is available throughout the conference for one-on-one meetings as well.
PTBI: 3.10 (unch)
PlasmaTech Biopharmaceuticals to Present at Biotech Showcase 2015
PR Newswire - Wed Jan 14, 8:00AM CST
PlasmaTech Biopharmaceuticals, Inc. (NASDAQ: PTBI, PTBIW), a biopharmaceutical company advancing patient care in critical areas, announced today that Scott Schorer, CEO, will be presenting at Biotech Showcase(TM) 2015 Conference being held in San Francisco, CA this week. Details are as follows:
PTBI: 3.10 (unch)
PlasmaTech Biopharmaceuticals To Present at OneMedForum Investor Conference in San Francisco
PR Newswire - Mon Jan 12, 8:15AM CST
PlasmaTech Biopharmaceuticals, Inc. (NASDAQ: PTBI, PTBIW), a biopharmaceutical company advancing patient care in critical areas, announced today that Scott Schorer, CEO, will be presenting a business overview and update at the OneMedForum investor conference Monday, January 12, 2015, in San Francisco. Details are as follows:
PTBI: 3.10 (unch)
InsiderInsights.com Daily Round Up 12/29/14: REGN, VRML, OAS, PTBI
InsiderInsights - at Seeking Alpha - Tue Dec 30, 12:23PM CST
GD: 137.61 (-0.54), SKBI: 4.22 (+0.03), PTBI: 3.10 (unch), FMD: 5.45 (-0.16), GHC: 976.65 (+15.51), VRML: 2.08 (+0.12), ADBE: 76.51 (+1.92), OHAI: 4.67 (+0.01), KERX: 11.63 (-0.60), BH: 416.41 (-1.55), LII: 104.27 (+0.88), JAZZ: 169.69 (+6.89), NMBL: 23.19 (+0.81), REGN: 402.40 (+0.66), OAS: 16.84 (-0.03), XLRN: 38.02 (+0.07), SYK: 94.51 (+1.14), CRM: 62.85 (+1.59)
PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering
PR Newswire - Wed Dec 24, 10:59AM CST
PlasmaTech Biopharmaceuticals, Inc. (NASDAQ: PTBI, PTBIW), a biopharmaceutical company advancing patient care in critical areas, announced the closing of an underwritten public offering of 3,500,000 shares of common stock, and warrants to purchase up to an aggregate 3,500,000 shares of common stock, at an offering price of $4.00 per share and $.01 per warrant. The warrants have a per share exercise price of $5.00, are exercisable immediately, and expire 5 years from the date of issuance.
PTBI: 3.10 (unch)
PlasmaTech prices public offering
Seeking Alpha - at Seeking Alpha - Fri Dec 19, 6:43AM CST
PTBI: 3.10 (unch)
PlasmaTech Biopharmaceuticals, Inc. Announces Pricing of $14,000,000 Public Offering and Listing on NASDAQ
PR Newswire - Thu Dec 18, 5:29PM CST
PlasmaTech Biopharmaceuticals, Inc. (NASDAQ: PTBI, PTBIW), a biopharmaceutical company advancing patient care in critical areas, announced the pricing of an underwritten public offering of 3,500,000 shares of common stock, and warrants to purchase up to an aggregate 3,500,000 shares of common stock, at an offering price of $4.00 per share and $.01 per warrant. The warrants have a per share exercise price of $5.00, are exercisable immediately, and expire 5 years from the date of issuance. The shares and warrants will begin trading on The NASDAQ Capital Market on December 19, 2014 under the symbols "PTBI" and "PTBIW," respectively.
PTBI: 3.10 (unch)
PlasmaTech Biopharmaceuticals To Present at 17th Annual BIO CEO & Investor Conference
PR Newswire - Fri Feb 06, 10:13AM CST
PlasmaTech Biopharmaceuticals, Inc. (NASDAQ: PTBI), a biopharmaceutical company advancing protein biologic therapies and oncology supportive care products, announced today that Scott Schorer, CEO, will be presenting a corporate update at the 17th Annual BIO CEO & Investor Conference. The presentation will take place on Monday, February 9, 2015, at 5:00 pm ET in the Park South room at the Waldorf Astoria Hotel in New York, NY. Management from PTBI is available throughout the conference for one-on-one meetings as well.
PTBI: 3.10 (unch)
PlasmaTech Biopharmaceuticals to Present at Biotech Showcase 2015
PR Newswire - Wed Jan 14, 8:00AM CST
PlasmaTech Biopharmaceuticals, Inc. (NASDAQ: PTBI, PTBIW), a biopharmaceutical company advancing patient care in critical areas, announced today that Scott Schorer, CEO, will be presenting at Biotech Showcase(TM) 2015 Conference being held in San Francisco, CA this week. Details are as follows:
PTBI: 3.10 (unch)
PlasmaTech Biopharmaceuticals To Present at OneMedForum Investor Conference in San Francisco
PR Newswire - Mon Jan 12, 8:15AM CST
PlasmaTech Biopharmaceuticals, Inc. (NASDAQ: PTBI, PTBIW), a biopharmaceutical company advancing patient care in critical areas, announced today that Scott Schorer, CEO, will be presenting a business overview and update at the OneMedForum investor conference Monday, January 12, 2015, in San Francisco. Details are as follows:
PTBI: 3.10 (unch)
InsiderInsights.com Daily Round Up 12/29/14: REGN, VRML, OAS, PTBI
InsiderInsights - at Seeking Alpha - Tue Dec 30, 12:23PM CST
GD: 137.61 (-0.54), SKBI: 4.22 (+0.03), PTBI: 3.10 (unch), FMD: 5.45 (-0.16), GHC: 976.65 (+15.51), VRML: 2.08 (+0.12), ADBE: 76.51 (+1.92), OHAI: 4.67 (+0.01), KERX: 11.63 (-0.60), BH: 416.41 (-1.55), LII: 104.27 (+0.88), JAZZ: 169.69 (+6.89), NMBL: 23.19 (+0.81), REGN: 402.40 (+0.66), OAS: 16.84 (-0.03), XLRN: 38.02 (+0.07), SYK: 94.51 (+1.14), CRM: 62.85 (+1.59)
PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering
PR Newswire - Wed Dec 24, 10:59AM CST
PlasmaTech Biopharmaceuticals, Inc. (NASDAQ: PTBI, PTBIW), a biopharmaceutical company advancing patient care in critical areas, announced the closing of an underwritten public offering of 3,500,000 shares of common stock, and warrants to purchase up to an aggregate 3,500,000 shares of common stock, at an offering price of $4.00 per share and $.01 per warrant. The warrants have a per share exercise price of $5.00, are exercisable immediately, and expire 5 years from the date of issuance.
PTBI: 3.10 (unch)
PlasmaTech prices public offering
Seeking Alpha - at Seeking Alpha - Fri Dec 19, 6:43AM CST
PTBI: 3.10 (unch)
PlasmaTech Biopharmaceuticals, Inc. Announces Pricing of $14,000,000 Public Offering and Listing on NASDAQ
PR Newswire - Thu Dec 18, 5:29PM CST
PlasmaTech Biopharmaceuticals, Inc. (NASDAQ: PTBI, PTBIW), a biopharmaceutical company advancing patient care in critical areas, announced the pricing of an underwritten public offering of 3,500,000 shares of common stock, and warrants to purchase up to an aggregate 3,500,000 shares of common stock, at an offering price of $4.00 per share and $.01 per warrant. The warrants have a per share exercise price of $5.00, are exercisable immediately, and expire 5 years from the date of issuance. The shares and warrants will begin trading on The NASDAQ Capital Market on December 19, 2014 under the symbols "PTBI" and "PTBIW," respectively.
PTBI: 3.10 (unch)
(0)
(0)Scroll down for more posts ▼